Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 8/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | GRB2 | P62993 | 1/20 | 0.37 |
| ▸ | TLR2 | O60603 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29938666 | 0.94 | PTPN1 (0.41) | PTPN1KMT2AGRB2TLR2 | |
| SCHEMBL29938443 | 0.92 | PTPN1 (0.43) | PTPN1KMT2ATLR2 | |
| SCHEMBL27094764 | 0.92 | PTPN1 (0.44) | PTPN1KMT2ATLR2 | |
| SCHEMBL27094763 | 0.92 | PTPN1 (0.44) | PTPN1KMT2ATLR2 | |
| SCHEMBL30948814 | 0.88 | PTPN1 (0.48) | PTPN1GRB2 | |
| SCHEMBL29938640 | 0.86 | PTPN1 (0.42) | PTPN1KMT2ATLR2 | |
| SCHEMBL27093791 | 0.85 | PTPN1 (0.44) | PTPN1KMT2ATLR2 | |
| SCHEMBL27093786 | 0.85 | PTPN1 (0.44) | PTPN1KMT2ATLR2 | |
| SCHEMBL30948772 | 0.85 | KMT2A (0.44) | KMT2ATLR2 | |
| SCHEMBL30919280 | 0.83 | PTPN1 (0.44) | PTPN1TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240398962-A1 | DENDRIMER-GLUTAMINE ANTAGONIST CONJUGATES AND METHODS OF USE THEREOF | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY (CZ) | 2024-12-05 | — | — | US | disclosed |
| EP-4322961-A1 | DENDRIMER-GLUTAMINE ANTAGONIST CONJUGATES AND METHODS OF USE THEREOF | The Johns Hopkins University (US) | 2024-02-21 | — | — | EP | disclosed |
| WO-2022221490-A1 | DENDRIMER-GLUTAMINE ANTAGONIST CONJUGATES AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240398962-A1 | DENDRIMER-GLUTAMINE ANTAGONIST CONJUGATES AND METHODS OF USE THEREOF | GLUL, GLS, GRM2 | PTPN1 3627/4885KMT2A 398/4885GRB2 1324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.